Frigy Attila, Belényi Boglárka, Kirchmaier Ádám, Fekete Nándor, Szabó István Adorján
Department of Internal Medicine IV, G.E, Palade University of Medicine, Pharmacy, Science and Technology of Tirgu Mures, Tirgu Mures, Romania.
Department of Physiopathology, G.E. Palade University of Medicine, Pharmacy, Science and Technology of Tirgu Mures, Tirgu Mures, Romania.
Case Rep Cardiol. 2020 May 24;2020:1642914. doi: 10.1155/2020/1642914. eCollection 2020.
Despite the recent, remarkable achievements in cardiology, heart failure (HF) remains a major public health problem due to its increasing prevalence, frequent hospitalizations, and significant mortality. Humoral biomarkers in HF are capable to reflect different aspects of the cardiac morpho-functional changes and the related pathophysiological processes and could have important diagnostic, prognostic, and therapeutical roles. CA-125 is a well-known tumor marker (mainly for ovarian cancer), and also a useful, but less applied cardiac biomarker. Practical aspects, possible pitfalls related with increased CA-125 levels are illustrated by two cases, both with HF, with the biomarker determined for other reasons and having high levels in the context of the cardiac decompensation. The paper presents a short review of the main biochemical, pathophysiological, and clinical data linked to CA-125, with special accent on its utility in patients with HF.
尽管近年来心脏病学取得了显著成就，但由于心力衰竭（HF）患病率不断上升、频繁住院以及死亡率高，它仍然是一个主要的公共卫生问题。HF中的体液生物标志物能够反映心脏形态功能变化的不同方面以及相关的病理生理过程，并且可能具有重要的诊断、预后和治疗作用。CA-125是一种众所周知的肿瘤标志物（主要用于卵巢癌），也是一种有用但应用较少的心脏生物标志物。本文通过两例HF患者的病例说明了与CA-125水平升高相关的实际情况及可能存在的问题，这两例患者因其他原因检测了该生物标志物，且在心脏失代偿情况下其水平较高。本文简要回顾了与CA-125相关的主要生化、病理生理和临床数据，特别强调了其在HF患者中的应用价值。
